p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells
- 906 Downloads
Increasing evidence suggests that an inflammatory microenvironment promotes invasion by glioblastoma (GBM) cells. Together with p38 mitogen-activated protein kinase (MAPK) activation being regarded as promoting inflammation, we hypothesized that elevated inflammatory cytokine secretion and p38 MAPK activity contribute to expansion of GBMs. Here we report that IL-1β, IL-6, and IL-8 levels and p38 MAPK activity are elevated in human glioblastoma specimens and that p38 MAPK inhibitors attenuate the secretion of pro-inflammatory cytokines by microglia and glioblastoma cells. RNAi knockdown and immunoprecipitation experiments suggest that the p38α MAPK isoform drives inflammation in GBM cells. Importantly, p38 MAPK inhibition strongly reduced invasion of U251 glioblastoma cells in an inflammatory microenvironment, providing evidence for a p38 MAPK-regulated link between inflammation and invasiveness in GBM pathophysiology.
KeywordsGlioblastoma Tumour microenvironment p38 MAPK inhibitors Inflammation Invasion
This study was supported by grants from the Cure for Life Foundation, Alzheimer’s Australia, and The JR and JO Wicking Foundations (managed by ANZ Trustees) to LM; the National Health and Medical Research Council of Australia (510293, 510294) and the University of Sydney (2010-02681) to TG; the Australian Research Council (DP1094232) to NB, and the National Health and Medical Research Council of Australia (1009914) to GG. The authors acknowledge scientific and technical input and support from the Australian Microscopy and Microanalysis Research Facility (AMMRF) at the University of Sydney.
- 2.Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, Tan P, Sah DW, Cavenee WK, Furnari FB (2011) EGFRvIII promotes glioma angiogenesis and growth through the NFκB, interleukin-8 pathway. Oncogene. doi: 10.1038/onc.2011.563
- 11.Tchirkov A, Khalil T, Chautard E, Mokhtari K, Véronèse L et al (2007) Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer 96:474–476Google Scholar
- 13.Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW et al (2010) Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24:1731–1745Google Scholar
- 20.Demuth T, Reavie LB, Rennert JL, Nakada M, Nakada S et al (2007) MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival. Mol Cancer Ther 6:1212–1222Google Scholar
- 25.Malchinkhuu E, Sato K, Horiuchi Y, Mogi C, Ohwada S et al (2005) Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response to lysophosphatidic acid and sphingosine-1-phosphate in glioma cells. Oncogene 24:6676–6688Google Scholar
- 28.Vila de Muga S, Timpson P, Cubells L, Evans R, Hayes TE et al (2009) Annexin A6 inhibits Ras signalling in breast cancer cells. Oncogene 28:363–377Google Scholar
- 34.Gao HM, Zhou H, Zhang F, Wilson BC, Kam W, Hong JS (2011) HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 31:1081–1092Google Scholar
- 49.Park MJ, Park IC, Hur JH, Kim MS, Lee HC et al (2002) Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase. J Neurosurg 97:112–118Google Scholar